Holen Sie sich die Stockscreener-App
4.52
2.38%
-0.11
Handel nachbörslich:
4.54
0.02
+0.44%
Schlusskurs vom Vortag:
$4.63
Offen:
$4.6
24-Stunden-Volumen:
14.67M
Relative Volume:
0.56
Marktkapitalisierung:
$1.93B
Einnahmen:
$64.60M
Nettoeinkommen (Verlust:
$-377.75M
KGV:
-2.9161
EPS:
-1.55
Netto-Cashflow:
$-335.64M
1W Leistung:
-7.09%
1M Leistung:
-22.07%
6M Leistung:
-30.14%
1J Leistung:
-25.90%
1-Tages-Spanne:
$4.46
$4.62
1-Wochen-Bereich:
$4.46
$4.895
52-Wochen-Spanne:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Firmenname
Recursion Pharmaceuticals Inc
Sektor
Branche
Telefon
(385) 269-0203
Adresse
41S RIO GRANDE STREET, SALT LAKE CITY
Vergleichen Sie RXRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
4.52 | 2.03B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-03-16 | Eingeleitet | Needham | Buy |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-04 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | Eingeleitet | Berenberg | Buy |
| 2021-05-11 | Eingeleitet | BofA Securities | Buy |
| 2021-05-11 | Eingeleitet | Goldman | Neutral |
| 2021-05-11 | Eingeleitet | JP Morgan | Neutral |
| 2021-05-11 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Recursion Pharmaceuticals Inc Aktie (RXRX) Neueste Nachrichten
Recursion Pharmaceuticals' Strategic Position in TechBio and Clinical Pipeline Progress - AInvest
Is Recursion Pharmaceuticals Inc. trending in predictive chart models2025 Investor Takeaways & High Accuracy Swing Entry Alerts - Newser
Aug Update: What is the Moat Score of Recursion Pharmaceuticals Inc.Risk Management & Low Volatility Stock Suggestions - khodrobank.com
How to escape a deep drawdown in Recursion Pharmaceuticals Inc.Long Setup & Real-Time Buy Signal Notifications - Newser
Analyzing recovery setups for Recursion Pharmaceuticals Inc. investorsJuly 2025 WrapUp & Real-Time Volume Trigger Notifications - Newser
Technical analysis overview for Recursion Pharmaceuticals Inc. stockJuly 2025 Momentum & Safe Investment Capital Preservation Plans - Newser
Using Ichimoku Cloud for Recursion Pharmaceuticals Inc. technicalsPortfolio Performance Report & Entry Point Confirmation Signals - Newser
How liquid is Recursion Pharmaceuticals Inc. stock2025 Investor Takeaways & Free High Accuracy Swing Entry Alerts - khodrobank.com
Real time alert setup for Recursion Pharmaceuticals Inc. performanceEarnings Risk Summary & Weekly Return Optimization Plans - Newser
Can machine learning forecast Recursion Pharmaceuticals Inc. recoveryJuly 2025 Summary & Fast Momentum Entry Tips - Newser
Recursion Pharmaceuticals Inc. stock prediction for this weekForecast Cut & Growth-Oriented Investment Plans - Newser
Recursion Pharmaceuticals shares rise 1.93% premarket as AI-driven drug discovery gains traction. - AInvest
Is now a turning point for Recursion Pharmaceuticals Inc.Weekly Trade Recap & Precise Trade Entry Recommendations - Newser
Pattern recognition hints at Recursion Pharmaceuticals Inc. upside2025 Dividend Review & Free High Accuracy Swing Entry Alerts - Newser
Detecting support and resistance levels for Recursion Pharmaceuticals Inc.Portfolio Value Summary & Fast Exit and Entry Strategy Plans - Newser
Will Recursion Pharmaceuticals Inc. benefit from macro trendsJuly 2025 Technicals & AI Driven Price Forecasts - Newser
Forecasting Recursion Pharmaceuticals Inc. price range with options data2025 Buyback Activity & Verified Short-Term Trading Plans - Newser
Visualizing Recursion Pharmaceuticals Inc. stock with heatmapsWeekly Earnings Recap & Real-Time Chart Breakout Alerts - Newser
What’s next for Recursion Pharmaceuticals Inc. stock priceJuly 2025 Big Picture & Safe Entry Point Identification - Newser
AI-driven drug discovery picks up as FDA pushes to reduce animal testing - Reuters
Will Recursion Pharmaceuticals Inc. stock recover after recent dropJuly 2025 Technicals & Free Long-Term Investment Growth Plans - Newser
Combining price and volume data for Recursion Pharmaceuticals Inc.July 2025 Snapshot & Fast Moving Stock Watchlists - Newser
Should I buy Recursion Pharmaceuticals Inc. stock nowJuly 2025 Weekly Recap & Consistent Profit Alerts - khodrobank.com
How to manage a losing position in Recursion Pharmaceuticals Inc.July 2025 Market Mood & Risk Managed Investment Strategies - Newser
Applying Wyckoff theory to Recursion Pharmaceuticals Inc. stockPortfolio Growth Summary & Intraday High Probability Setup Alerts - Newser
How high can Recursion Pharmaceuticals Inc. stock goEarnings Overview Summary & Long-Term Safe Investment Plans - Newser
Earnings visualization tools for Recursion Pharmaceuticals Inc.Quarterly Performance Summary & Weekly High Return Stock Opportunities - Newser
Does Recursion Pharmaceuticals Inc. stock reflect fundamentalsJuly 2025 Breakouts & Growth Focused Stock Reports - khodrobank.com
Can Recursion Pharmaceuticals Inc. expand into new marketsMarket Trend Summary & Reliable Price Breakout Signals - khodrobank.com
Tools to monitor Recursion Pharmaceuticals Inc. recovery probabilityQuarterly Growth Report & Detailed Earnings Play Alerts - Newser
Is Recursion Pharmaceuticals Inc. building a consolidation base2025 Biggest Moves & Real-Time Volume Triggers - Newser
Real time pattern detection on Recursion Pharmaceuticals Inc. stock2025 Breakouts & Breakdowns & Weekly Breakout Opportunity Watchlist - Newser
Can Recursion Pharmaceuticals Inc. hit a new high this monthMarket Growth Report & Weekly High Potential Stock Alerts - Newser
Volatility clustering patterns for Recursion Pharmaceuticals Inc.2025 Technical Overview & Free Fast Entry Momentum Trade Alerts - Newser
Will Recursion Pharmaceuticals Inc. see short term momentumDividend Hike & Risk Controlled Daily Trade Plans - Newser
Market reaction to Recursion Pharmaceuticals Inc.’s recent newsQuarterly Trade Summary & Precise Swing Trade Alerts - Newser
What earnings revisions data tells us about Recursion Pharmaceuticals Inc.2025 Top Gainers & Reliable Price Breakout Alerts - Newser
Momentum divergence signals in Recursion Pharmaceuticals Inc. chartJuly 2025 EndofMonth & Reliable Volume Spike Alerts - Newser
Multi factor analysis applied to Recursion Pharmaceuticals Inc.Dividend Hike & Long-Term Growth Plans - Newser
Quantitative breakdown of Recursion Pharmaceuticals Inc. recent moveWeekly Investment Summary & Free High Return Stock Watch Alerts - Newser
Applying chart zones and confluence areas to Recursion Pharmaceuticals Inc.Portfolio Update Report & Weekly Hot Stock Watchlists - Newser
Needham Maintains Buy Rating on Recursion (RXRX) - MSN
Performance Recap: Is Recursion Pharmaceuticals Inc. a strong growth stockQuarterly Risk Review & Short-Term Swing Trade Alerts - خودرو بانک
Historical volatility pattern of Recursion Pharmaceuticals Inc. visualizedTrade Exit Report & AI Powered Market Trend Analysis - Newser
Momentum Screeners Rank Recursion Pharmaceuticals Inc. in Top 5 TodayPortfolio Gains Summary & Daily Technical Stock Forecast Reports - beatles.ru
Finanzdaten der Recursion Pharmaceuticals Inc-Aktie (RXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):